The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1360
Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug.1 Many combination products have been marketed; the latest of these combines saxagliptin2 with extended-release (ER) metformin as Kombiglyze XR.

MECHANISM OF ACTION — Saxagliptin, an oral dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, slows breakdown of glucagon-like peptide-1 (GLP-1), which increases release of insulin from pancreatic beta cells and decreases release of glucagon from pancreatic alpha cells. Metformin decreases hepatic glucose production and increases insulin sensitivity in peripheral tissues.

CLINICAL STUDIES — Monotherapy vs. Combination Therapy – FDA approval of Kombiglyze XR was based ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Saxagliptin Metformin (Kombiglyze XR) for Type 2 Diabetes
Article code: 1360a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian